PDCD1 and hepatocellular carcinoma: To date, several immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein-1 (PD-1), or its ligand programmed cell death-ligand 1 (PD-L1) have been approved by the U.S. Food and Drug Administration (FDA) for various types of cancers, including HCC (10–12).